News | Endovascular Aortic Repair | November 21, 2018

Obese Patients Have More Post-Op Problems Following AAA Repair

Study finds obese patients have higher rates of renal failure and wound infection after endovascular abdominal aortic aneurysm repair

Obese Patients Have More Post-Op Problems Following AAA Repair

November 21, 2018 — New research in the December edition of the Journal of Vascular Surgery suggests significant increase in morbidities in obese patients after open surgery, but not after endovascular abdominal aortic aneurysm (AAA) repair.1

Researchers found that obese patients were more likely to have longer procedures and to lose more blood than those who were not obese, and obese patients were more likely to have post-operative problems such as renal failure or wound infections.

In this new study, researchers from Johns Hopkins University, led by vascular surgeon Mahmoud Malas, M.D., performed a retrospective analysis of prospectively collected data by the Vascular Quality Initiative (2003-2017). The aim of the study was comparing in-hospital outcomes in obese (body mass index >30) vs non-obese patients undergoing AAA repair.

“In this large national sample of an elective AAA cohort,” said Malas, “obese patients had similar in-hospital mortality compared with non-obese patients in both open and endovascular repairs. The results remained unchanged even after looking at different subclasses of obesity, including those with BMI >40.”

Previous work defining early outcomes after AAA in the obese has yielded conflicted results. Recent meta-analysis suggested the superiority of endovascular repair over open, but only four studies with relatively small numbers were included. Single-center studies have either corroborated this conclusion or failed to demonstrate a difference.

The new study ultimately evaluated 33,082 procedures including both:

  • Open repair (non-obese, n=4,604, obese, n=1,754); and
  • Endovascular repair (non-obese, n=18,338, obese, n=8,385).

Demographic analysis revealed that the obese patients, compared to the non-obese, were:

  • Younger (67.6 vs 70.3 years old);
  • Male (open repair, 76 percent vs 73 percent, endovascular repair, 82 percent vs 81 percent); and
  • More likely to have significant comorbid conditions (diabetes, hypertension, coronary artery disease, and congestive heart disease).

Evaluation of the operations revealed that the obese had:

  • Higher blood loss (open, 2,030 vs 1,617ml, endovascular 228 vs 207ml); and
  • Longer operations (open 259 vs 239 mins, endovascular 138 vs 134 mins).

With regards to outcomes, there was no difference in mortality between the groups for either repair method (open 3 percent vs 3 percent, endovascular 0.5 percent vs 0.6 percent).

However, following open repair, the obese patients had higher odds of developing:

  • Renal failure (1.33 odds ratio); and
  • Wound infection (1.75 odds ratio).

“Wound infection is a common complication seen among obese patients undergoing all surgical procedures. Even after adjusting for comorbid conditions, the obese had 75 percent higher odds of wound infection following open repair, with the highest rates observed in the more severely obese patients,” noted Malas.

“In this study open repair showed increased risk of all in-hospital complications compared with endovascular therapy for AAA,” Malas said, “corroborating the known superiority of endovascular repair over open repair seen in the literature.”

While weight reduction itself would be considered important, this is not always possible in cases where more urgent care is necessary, such as AAA. With the prevalence of significant obesity in the United States as high as 39.8 percent, understanding its impact on the outcomes of various medical procedures is key in delivering safe and cost-effective healthcare.

This research article is open source here through Jan. 31, 2019.

For more information: www.jvascsurg.org

Reference

1. Locham S., Rizwan M., Dakour-Aridi H., et al. Outcomes after elective abdominal aortic aneurysm repair in obese versus nonobese patients. Journal of Vascular Surgery, published online June 7, 2018. https://doi.org/10.1016/j.jvs.2018.03.414

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init